Publications

Preclinical
Festival of Biologics
October 10, 2023
TOPO1i ADC Platform From Concept to Pipeline Application
Mark Petersen
View Publication
Preclinical
World Bispecific Summit
October 2, 2023
Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors
Nina Weisser
View Publication
Preclinical
Journal of Medicinal Chemistry
June 12, 2023
Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads
Petersen et al.
View Publication
Zanidatamab
ASCO
June 2, 2023
Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)
Pant et al.
View Publication
Zanidatamab
ASCO
June 4, 2023
Zanidatamab, a HER2-targeted Bispecific Antibody, in Combination With Docetaxel as First-line Therapy for Patients With Advanced HER2-positive Breast Cancer: Updated Results From a Phase 1b/2 Study
Wang et al.
View Publication
Zanidatamab
Lancet Oncology
June 2, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Harding et al.
View Publication
Preclinical
Bioorganic & Medicinal Chemistry Letters
June 2, 2023
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Brant et al.
View Publication
Preclinical
PEGS
May 15 - May 19, 2023
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
View Publication
ZW171
PEGS
May 19, 2023
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
Piscitelli et al.
View Publication
Preclinical
PEGS
May 15 - May 19, 2023
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Bhojane et al.
View Publication